Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Aug 07, 2024 8:55pm
329 Views
Post# 36168702

Broader view of things

Broader view of thingsThe whole process of re- aligning financial opportunities, needs to be seen in proper context.
Some yamner on about dillution, lack of deals etc .
First, as I stated the recent announcement is a Cary forward of existing ATM, only changing the agent.
NOT as additional amount.
Second, the point of dillution?
unless anothe4 source of $$ comes up, they need to raise funds to keep the business running.
Dillution only matters undef a few scinarios.
1. If they pay dividends , which they don't.
2. on an overall company buyout. ...They coman6 would be bough5 based on present value if future income/ number of shares.

so, the real question is, can they create more company  value to off set the number of shares?

Listening to the Q2 results, the following statement justifies, keeping the doors open.
" positive overall survival resukts from bracelet MBc study, expected before  end of this year, will strengthen our negotiation position"
simple answer.
assuming they did not source $$ by usdu8ng shares... then they would have to negotiate from a position of weakness &/ or close down.
meaning shareholder value would be minimal.
assuming the MBc resukts come in as expected, then they can negotiate from a stronger position.
The on going additional arm of pancreatic cancer treatment alone , could lead to a third registration trial.
again, increasing potential value of the company.
All markets are all over the place right now.
like all opportunities, sometimes hard to see.
equally as hard to buy in.. lots of fear right now.
those who can only see value of a company based in its shareprice. Vs potential value of shareprice, 
ONC potential?
We will see that unfold once the MBc O.S. Numbers are made public.
until then, at the mercy of the market.
reminder.
The onkybreason Onc exists is to get Pelareorep approved for cancer treatment.
right now, as you read this they have strong support from CGAR, based on phase 2 pancreatic trial results.
Both the MBc & panc cancer phase 2 trials resulted in FDA fast track designstion.
I could go on.
point being Onc is worth a lot more than what it is trading at.
and potentially multiples higher in the near future.



<< Previous
Bullboard Posts
Next >>